Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 1 Diabetes (Juvenile Diabetes). According to Globaldata, it is involved in 9 clinical trials, of which 4 are ongoing, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Icovamenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Icovamenib is expected to reach an annual total of $106 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Icovamenib Overview

Icovamenib (BMF-219) is under development for the treatment of relapsed and refractory leukemia including mixed-lineage leukemia rearrangement (MLL-r) acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, relapsed and refractory chronic lymphocytic leukemia, NPM1 mutant acute myeloid leukemia, KRAS mutant solid tumors including colorectal, non-small cell lung cancer, pancreatic ductal adenocarcinoma diffuse large B-cell lymphoma (DLBCL), multiple myeloma, lung and pancreatic tumors. The drug is administered through oral route. It acts by targeting menin. It is under development for type 1/2 diabetes. It is being developed based on  FUSION platform.

Biomea Fusion Overview

Biomea Fusion is a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers. The company is headquartered in Palo Alto, California, the US.
The operating loss of the company was US$83.6 million in FY2022, compared to an operating loss of US$41.7 million in FY2021. The net loss of the company was US$81.8 million in FY2022, compared to a net loss of US$41.6 million in FY2021.

For a complete picture of Icovamenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.